Jun 17, 2021 13:24 Source: BSE
Sharon Bio Medicine - Compliances-Reg.24(A)-Annual Secretarial Compliance
With reference to the captioned subject and in compliance with the provisions of Regulation 24A of SEBI (LODR) Amendment Regulations, 2018, read with SEBI Circular bearing reference''CIR/CFD/CMDl/27 /2019'' dated February 08, 2019, please find enclosed Annual Secretarial Compliance Report of the Company issued by M/s. Kotak & Associates for the financial year ended 31st March, 2021. Kindly take the same on your records.
Jun 17, 2021 13:20 Source: BSE
Sharon Bio Medicine - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Clause 47 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR) we enclose advertisements given in Free Press Journal and Navshakti relating to the consideration and approval of Audited Financial Results of the Company for the quarter and year ended March 31, 2021. Kindly take the same on your records.
Jun 16, 2021 16:12 Source: BSE
Sharon Bio Medicine - Board Meeting Intimation for Audited Financial Results For The Financial Year Ended March 31, 2021
SHARON BIO-MEDICINE LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/06/2021 ,inter alia, to consider and approve Dear Sir/Madam, Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Audited Financial Results of the Company for the quarter and year ended March 31, 2021 along with the Auditor's Report thereon will be considered and approved on Wednesday, June 23, 2021 at the corporate office of the Company. As per the Company''s code of conduct to regulate, monitor and report trading in securities of the Company, the trading window for dealing in the securities of the Company was closed from April 1, 2021 and will open Forty-Eight (48) hours after the declaration of said financial results for the quarter and year ended March 31, 2021. This is for your information and record.
Apr 30, 2021 20:33 Source: BSE
Sharon Bio Medicine - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
|Sr. No. ||Particulars ||Details |
|1||Name of Compay||SHARON BIO-MEDICINE LTD.-|
|3 ||Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) ||891.40|
|4||Highest Credit Rating during the previous FY ||-|
|4a||Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)||Not Applicable|
|5||Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the framework||BSE|
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES
Name of the Company Secretary: Komal Mota
Designation: Company Secretary
Name of the Chief Financial Officer: Kaushik Banerjee
Designation: Chief Executive Officer
Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Apr 28, 2021 14:02 Source: BSE
Sharon Bio Medicine - Regulation 40(9) Of The SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015
Dear Sir /Madam, In compliance of Regulation 40(9) of the SESI (Listing Obligation & Disclosure Requirements) Regulation 2015, the Certificate for the Half Year Ended on March 31, 2021 as Certified by Company Secretary in Whole time in practice is submitted herewith. Kindly note and acknowledge the Same. Thanking You.
Apr 21, 2021 18:35 Source: BSE
Sharon Bio Medicine - Shareholding for the Period Ended March 31, 2021
Sharon Bio-Medicine Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here
Apr 20, 2021 19:09 Source: BSE
Sharon Bio Medicine - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the above referred subject, we are enclosing herewith the Confirmation Certificate dated April 05, 2021, received from M/s. Link Intime India Private Limited, the Register and Share Transfer Agent of our Company for the quarter ended March 31, 2021. Kindly take the same on your record and acknowledge the receipt. Thanking You,
Apr 20, 2021 18:54 Source: BSE
Sharon Bio Medicine - Compliance Of Clause 7 (3) Of The Listing Obligations And Disclosure Requirements
Regulations, 2015 (LODR) For Half Year Ended 31St March 2021
As per the requirement of Regulation 7 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we hereby confirm that activities in relation to both physical and electronic share transfer facility are maintained during the period October 1, 2020 to March 31, 2021 (both days inclusive) by the Company''s Registrar and Share Transfer Agent1 viz,, Link Intime India Private Limited, which is registered as Registrar & Share Transfer Agent, Category -I with the Securities and Exchange Board pf India vide Registration Number : INR000004058. Thanking You,
Apr 15, 2021 14:24 Source: BSE
Sharon Bio Medicine - Statement Of Investor Complaints For The Quarter Ended March 2021
| No.of Investor complaints pending at the beginning of the quarter || No.of Investor complaints received during the quarter|| No.of Investor complaints disposed of during the quarter || No.of Investor complaints unresolved at the end of the quarter |
| Name of the Signatory || :- ||Kaushik Banerjee|
|Designation || :- ||Chief Executive Officer|